Zhejiang Hisun Pharmaceutical Co., Ltd.

600267

CNE0000013Z2

Zhejiang Hisun Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of specialty bulk pharmaceutical chemicals and preparation products. The Company's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infection drugs, endocrine control drugs, anthelmintic, as well as animal remedies, among others. The Company is also engaged in the sales of drugs manufactured by other companies. The Company distributes its products in domestic markets and to overseas markets.

Employees

8,062

Sector

Pharmaceuticals

Calendar

2024-10-27 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

7.040CNY

Average target price

6.300CNY

Spread / Average Target

-10.51%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2024-09-20			5-day change	1st Jan Change
7.040 ^CNY	-1.40%		-1.12%	-24.79%

Aug. 19	Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
Aug. 06	Hisun Pharmaceutical Gets Nod to Market Eltrombopag; Shares Up 3%	MT

Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 19	CI
Hisun Pharmaceutical Gets Nod to Market Eltrombopag; Shares Up 3%	Aug. 06	MT
Hisun Pharmaceutical's Unit Gets Nod for Veterinary Drug	Jul. 23	MT
Shanghai Anrui Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 48 million in funding from Zhejiang Hisun Pharmaceutical Co., Ltd.	Jul. 15	CI
Hisun Pharmaceutical's Veterinary Arm Gets Registration Certificate for Mirtazapine Ointment	Jul. 12	MT
Hisun Pharmaceutical's Leukemia Drug Passes Chinese Drug Regulator's Consistency Evaluation	Jun. 27	MT
Hisun Pharmaceutical's Leukemia Drug Gets Marketing Approval	Jun. 27	MT
Hisun Pharmaceutical Unit's Cladribine Injection Passes Regulatory Evaluation	Jun. 19	MT
Hisun Pharmaceutical's Veterinary Arm Gets Nod to Produce Fenbendazole Oral Suspension	Jun. 04	MT
Hisun Pharma's Veterinary Arm Gets Approval to Register Amoxicillin and Clavulanate Potassium Dry Suspension	May. 20	MT
Hisun Pharma's Veterinary Arm Gets Nod to Market Selamectin Drops	May. 16	MT
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023.	Apr. 19	CI
Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback announced on December 23, 2023, has closed with 11,687,200 shares, representing 0.98% for CNY 98.99 million.	Apr. 17	CI
Hisun Pharma's Unit Gets Nod for Pig Vaccine	Apr. 17	MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023.	Apr. 01	CI
China Energy Engineering Issues Apology Over Former Director's Stake Disposal Breaches	Mar. 27	MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023.	Jan. 02	CI
Zhejiang Hisun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	Dec. 22	CI
Zhejiang Hisun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	Dec. 21	CI
Gogox Holdings Chairman Steps Down	Dec. 18	MT
Hisun Pharmaceutical's Unit Gets Certification for Imported Drug from Pfizer	Dec. 15	MT
Hisun Pharmaceutical CFO Resigns	Nov. 30	MT
Hisun Pharmaceutical's Unit Gets Import Drug Certificate for Methylprednisolone Tablets	Nov. 29	MT

Zhejiang Hisun Pharmaceutical Co., Ltd.

Equities